Results 251 to 260 of about 1,341,600 (296)

When Minimal Becomes Massive: A Case Report of Childhood-Onset Minimal Change Disease Marching to End Stage Renal Disease Despite Modern Immunotherapy. [PDF]

Clin Med Insights Case Rep
Zetawi M, Salameh H, Assi MK, Aldarak S, Altiti SR.   +4 more
europepmc   +1 more source

Clinical Importance of Central Sensitization and Neuropathic Pain in The Treatment and Follow-Up of Patients with Psoriasis and Psoriatic Arthritis.

Indian J Dermatol
Koca TT, Göğebakan H, Nazik H, Çetin G, Öztürk P.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Minimal disease activity in Gaucher disease: Criteria for definition

Molecular Genetics and Metabolism, 2012
Gaucher disease type I is a metabolic disorder caused by a genetic deficiency of lysosomal β-glucocerebrosidase that leads to accumulation of glucocerebroside in macrophages, thus causing damage in different organ systems. Enzyme replacement therapy with imiglucerase improves organ impairment and clinical manifestations, but patients differ in response
Maja Di Rocco, Generoso Andria, Bruno Bembi, Francesca Carubbi, GIONA, Fiorina, Gaetano Giuffrida, Silvia Linari, Michelina Sibilio, Vincenzo Spina, Maria Domenica Cappellini   +9 more
openaire   +2 more sources

Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis

Journal of Neurology, Neurosurgery & Psychiatry, 2020
ObjectiveThis study aimed to define the minimal evidence of disease activity (MEDA) during treatment that can be tolerated without exposing patients with relapsing-remitting multiple sclerosis at risk of long-term disability.MethodsWe retrospectively collected data of patients followed up to 10 years after starting interferon beta or glatiramer acetate.
Prosperini, Luca, Mancinelli, Chiara, Haggiag, Shalom, Cordioli, Cinzia, De Giglio, Laura, De Rossi, Nicola, Galgani, Simonetta, Rasia, Sarah, Ruggieri, Serena, Tortorella, Carla, Pozzilli, Carlo, Gasperini, Claudio   +11 more
openaire   +2 more sources

Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis

The Journal of Rheumatology, 2016
Objective.An international task force has recommended that disease remission or minimal disease activity (MDA) be the target of treatment for psoriatic arthritis (PsA) and that remission or MDA should be attained within 6 months of initiating medication.
Barry J, Sheane, Arane, Thavaneswaran, Dafna D, Gladman, Vinod, Chandran   +3 more
openaire   +2 more sources

Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity

Rheumatology International, 2015
The aim of this study was to investigate the presence of subclinical atherosclerosis among psoriatic arthritis (PsA) patients without any cardiovascular disease (CVD) or traditional cardiovascular risk factors through measurement of endothelial function and carotid intima-media thickness (IMT) and correlated with disease-related risk factors.
Kir, HALE, Unlu, BERRİN, ÇEFLE, AYŞE, YILMAZER, Baris, ŞAHİN, TAYFUN   +4 more
openaire   +5 more sources